文献速递消化道肿瘤与早癌消化内镜

结肠镜检查与粪便免疫化学检测降低结直肠癌死亡率的比较(CONFIRM):研究设计原理

Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design.
PubMed 文献 · Am J Gastroenterol · 2017-10-10

CONFIRM是一项在46家退伍军人事务医疗中心开展的大型实用性多中心随机平行组试验,计划纳入50,000名50-75岁平均风险个体,比较结肠镜筛查与年度粪便免疫化学检测(FIT)对结直肠癌死亡率的预防效果,主要终点为10年结直肠癌死亡率。

要点

  • CONFIRM在46家退伍军人事务医疗中心随机分配50,000名50-75岁平均风险个体接受结肠镜或年度FIT筛查。
  • 主要终点为结直肠癌死亡率,次要终点包括结直肠癌发病率、结肠镜并发症及结肠镜医师特征与肿瘤检出等的关联。
  • FIT阳性者转诊结肠镜,参与者每年接受调查以确定是否行结肠镜或诊断为结直肠癌。

核心结论

  • CONFIRM将比较结肠镜筛查与年度FIT筛查项目在预防结直肠癌死亡率方面是否更优,主要终点为10年结直肠癌死亡率。
  • 完成后CONFIRM将成为退伍军人事务系统内开展的最大干预试验(ClinicalTrials.gov标识:NCT01239082)。

研究设计与样本

  • CONFIRM是一项大型实用性多中心随机平行组试验,比较结肠镜筛查与年度粪便免疫化学检测(FIT)。
  • 计划纳入50,000名平均风险个体,从46家退伍军人事务(VA)医疗中心招募50-75岁、应接受结直肠癌筛查的合格个体。
  • 参与者被随机分配至结肠镜组或年度FIT组;结肠镜结果按常规诊疗管理并评估并发症,FIT阳性者转诊结肠镜。
  • 参与者每年接受调查以确定是否行结肠镜或诊断为结直肠癌;主要终点为结直肠癌死亡率。
  • 次要终点为:(1)结直肠癌发病率;(2)筛查结肠镜的并发症;(3)结肠镜医师特征与肿瘤检出、并发症及结肠镜后结直肠癌之间的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Colorectal cancer (CRC) is preventable through screening, with colonoscopy and fecal occult blood testing comprising the two most commonly used screening tests. Given the differences in complexity, risk, and cost, it is important to understand these tests' comparative effectiveness. STUDY DESIGN: The CONFIRM Study is a large, pragmatic, multicenter, randomized, parallel group trial to compare screening with colonoscopy vs. the annual fecal immunochemical test (FIT) in 50,000 average risk individuals. CONFIRM examines whether screening colonoscopy will be superior to a FIT-based screening program in the prevention of CRC mortality measured over 10 years. Eligible individuals 50-75 years of age and due for CRC screening are recruited from 46 Veterans Affairs (VA) medical centers. Participants are randomized to either colonoscopy or annual FIT. Results of colonoscopy are managed as per usual care and study participants are assessed for complications. Participants testing FIT positive are referred for colonoscopy. Participants are surveyed annually to determine if they have undergone colonoscopy or been diagnosed with CRC. The primary endpoint is CRC mortality. The secondary endpoints are (1) CRC incidence (2) complications of screening colonoscopy, and (3) the association between colonoscopists' characteristics and neoplasia detection, complications and post-colonoscopy CRC. CONFIRM leverages several key characteristics of the VA's integrated healthcare system, including a shared medical record with national databases, electronic CRC screening reminders, and a robust national research infrastructure with experience in conducting large-scale clinical trials. When completed, CONFIRM will be the largest intervention trial conducted within the VA (ClinicalTrials.gov identifier: NCT01239082).

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Dominitz JA, Robertson DJ, Ahnen DJ, et al. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design. Am J Gastroenterol. 2017. PMID: 29016565. doi:10.1038/ajg.2017.286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。